The decline in RAPT Therapeutics shares is directly attributed to the company's Q1 financial results. Typically, financial results can have a significant impact on stock prices, especially if they fall short of market expectations. The immediate negative reaction suggests that the results may have been below investor expectations, leading to a decrease in stock value.